Literature DB >> 12601294

Prevalence and risk factors for hepatitis B virus infections among STD patients in northeast region of Iran.

Javad Ghanaat1, Ali Sadeghian, Kiarash Ghazvini, M Reza Nassiri.   

Abstract

BACKGROUND: In many parts of the world, sexual transmission of hepatitis B virus plays a major role in acquisition of infections. In Northeast region of Iran the prevalence rate and risk factors influencing this type of transmission was not investigated. Therefore, the concurrence of hepatitis B virus (HBV) and STDs was studied to determine the prevalence and risk factors of sexual transmission of hepatitis B virus. MATERIAL/
METHODS: This study was carried out among 1500 attendances to the laboratories for STDs examination between 1998 and 2000. Those who were positive for STDs (syphilis & gonorrhea) were examined for HBV infection by determination of hepatitis B surface antigen (HBsAg). The data was analyzed and compared to the normal population.
RESULTS: The prevalence of STD in this population was 4.66% for syphilis and 6% for gonorrhea. Among this population the seroprevalence of HBsAg was 10% in women and 14.2% in men (mean seroprevalence of HBsAg was 13.13%). The concurrence of hepatitis B virus and syphilis was 14.28% which was slightly higher than concurrence for gonorrhea (12.22%).
CONCLUSIONS: The prevalence of HBV in our patient population was high, exceeding the national estimates. This population also represents a high-risk group in Northeast of Iran. Further, our data indicates that such high prevalence is significantly more evident in patients with low socioeconomic status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601294

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  1 in total

1.  The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran.

Authors:  Farhad Fathimoghaddam; Mohammad Reza Hedayati-Moghaddam; Hamid Reza Bidkhori; Sanaz Ahmadi; Hamid Reza Sima
Journal:  Hepat Mon       Date:  2011-05       Impact factor: 0.660

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.